Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis
- PMID: 34033068
- DOI: 10.1007/s42000-021-00289-z
Higher ovulation rate with letrozole as compared with clomiphene citrate in infertile women with polycystic ovary syndrome: a systematic review and meta-analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common cause of anovulatory infertility. According to the latest guidelines, letrozole should be considered as the first-line pharmacological treatment for women with WHO Group II anovulation or PCOS. However, the use of letrozole as an ovulation induction agent is not FDA or EMA approved, and its use is "off-label." The main concern with respect to letrozole regards its potential teratogenic effect on the fetus.
Purpose: To determine whether the probability of ovulation is higher with letrozole as compared to clomiphene citrate (CC) in anovulatory women with PCOS.
Methods: Randomized controlled trials (RCTs) comparing letrozole versus CC used for ovulation induction in infertile women with PCOS followed by timed intercourse (TI) or intrauterine insemination (IUI) were included in this meta-analysis. Primary outcome was ovulation. Secondary outcomes were live birth, clinical pregnancy, miscarriage, multiple pregnancy, and congenital anomalies. Subgroup analysis included patients who received letrozole or CC as first-line treatment, and patients with PCOS diagnosed according to the Rotterdam criteria.
Results: Twenty-six RCTs published between 2006 and 2019, involving 4168 patients who underwent 8310 cycles of ovulation induction, were included. The probability of ovulation was significantly higher in letrozole as compared to CC cycles (RR: 1.148, 95% CI: 1.077 to 1.223, 3017 women, 19 trials, I2: 47.7%, low-quality evidence).
Conclusion: A higher probability of ovulation is expected in infertile patients with PCOS treated with letrozole as compared to CC. The higher ovulation rate might have contributed to the higher clinical pregnancy and live birth rate. This finding is also true for patients who were administered letrozole as first-line treatment.
Trial registration: CRD42019125166.
Keywords: Clomiphene citrate; Letrozole; Meta-analyses; Ovulation; Ovulation induction therapy; PCOS; Systematic review.
© 2021. Hellenic Endocrine Society.
Similar articles
-
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2018 May 24;5(5):CD010287. doi: 10.1002/14651858.CD010287.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Sep 27;9:CD010287. doi: 10.1002/14651858.CD010287.pub4. PMID: 29797697 Free PMC article. Updated.
-
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. Cochrane Database Syst Rev. 2022. PMID: 36165742 Free PMC article.
-
Aromatase inhibitors for subfertile women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2014 Feb 24;(2):CD010287. doi: 10.1002/14651858.CD010287.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2018 May 24;5:CD010287. doi: 10.1002/14651858.CD010287.pub3. PMID: 24563180 Updated.
-
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review.Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:38-62. doi: 10.1016/j.ejogrb.2022.01.025. Epub 2022 Feb 1. Eur J Obstet Gynecol Reprod Biol. 2022. PMID: 35149444
-
Comparison of Letrozole and Clomiphene Citrate in Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.Reprod Sci. 2024 Apr;31(4):883-905. doi: 10.1007/s43032-023-01404-8. Epub 2023 Nov 29. Reprod Sci. 2024. PMID: 38030814
Cited by
-
Insulin-sensitizing agents for infertility treatment in woman with polycystic ovary syndrome: a narrative review of current clinical practice.Hormones (Athens). 2024 Mar;23(1):49-58. doi: 10.1007/s42000-023-00494-y. Epub 2023 Oct 4. Hormones (Athens). 2024. PMID: 37792213 Review.
-
Sequential 2.5 mg letrozole/FSH therapy is more effective for promoting pregnancy in infertile women with PCOS: a pragmatic randomized controlled trial.Front Endocrinol (Lausanne). 2024 Jan 15;14:1294339. doi: 10.3389/fendo.2023.1294339. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38283747 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Cangfu Daotan Decoction in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.Evid Based Complement Alternat Med. 2022 May 17;2022:4395612. doi: 10.1155/2022/4395612. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35620410 Free PMC article.
-
New insights into the ovulatory process in the human ovary.Hum Reprod Update. 2025 Jan 1;31(1):21-47. doi: 10.1093/humupd/dmae027. Hum Reprod Update. 2025. PMID: 39331957 Free PMC article. Review.
-
Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review.Rev Recent Clin Trials. 2025;20(2):113-123. doi: 10.2174/0115748871325070241008101355. Rev Recent Clin Trials. 2025. PMID: 39421989 Review.
References
-
- Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352(12):1223–1236. https://doi.org/10.1056/NEJMra041536 - DOI - PubMed
-
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745–2749. https://doi.org/10.1210/jc.2003-032046 - DOI - PubMed
-
- Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO (2016) The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 31(12):2841–2855. https://doi.org/10.1093/humrep/dew218 - DOI - PubMed
-
- Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome [published correction appears in Hum Reprod. 2008 Jun;23(6):1474]. Hum Reprod 23(3):462–477. https://doi.org/10.1093/humrep/dem426 - DOI
-
- ESHRE Capri Workshop Group (2012) Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 18(5):586–599. https://doi.org/10.1093/humupd/dms019 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials